Abstract: Molybdenum complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The molybdenum complexes correspond in structure to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen, alkyl, and trialkylsilyl; and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 is trialkylsilyl.
Abstract: The invention relates to a reactive mesogen (RM) formulation comprising a conductive additive, to a polymer film obtained thereof, and the use of the RM formulation and polymer film in optical or electrooptical components or devices, like optical retardation films for liquid crystal displays (LCDs).
Type:
Grant
Filed:
June 22, 2017
Date of Patent:
August 18, 2020
Assignee:
Merck Patent GmbH
Inventors:
Graham Smith, Owain Llyr Parri, Vicki Cook, Georg Bernatz, David Wilkes, Jonathan Henry Wilson, Mark James, Philip Edward May
Abstract: The present invention relates to alkaline earth aluminate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
August 18, 2020
Assignee:
MERCK PATENT GMBH
Inventors:
Aleksander Zych, Mathias Rapphahn, Ralf Petry, Ingo Koehler, Andreas Benker, Stefan Tews
Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
Abstract: The invention relates to a liquid crystal mixture characterised in that it comprises one or more photoreactive mesogens of formula I wherein the parameters and groups occurring are defined as indicated in claim 1, to a process for the fabrication of liquid crystal displays using these liquid crystal mixtures and to a liquid crystal display obtainable by this process. The invention further relates to new compounds of formula I.
Type:
Application
Filed:
December 2, 2016
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Kevin ADLEM, Alex DAVIS, Joseph SARGENT, Ian Charles SAGE, Edward PLUMMER, Izumi SAITO, Rocco FORTTE, Helga HAAS, Lars LIETZAU
Abstract: The present application relates to a liquid-crystalline material comprising a sterically hindered N-oxide and a dye. The invention furthermore relates to the use of the liquid-crystalline material in an optical switching device for regulation of the passage of sunlight.
Type:
Application
Filed:
May 16, 2017
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Michael JUNGE, Ursula PATWAL, Ewa Dominica PTAK
Abstract: A light modulation element comprising, preferably consisting of a cholesteric liquid crystalline medium sandwiched between two opposing substrates, an electrode arrangement, which is capable to allow the application of an electric field, which is substantially perpendicular to the main plane of substrate or the layer of the cholesteric liquid-crystalline medium, characterized in that one of the substrates is provided with a processed alignment layer adjacent to the cholesteric liquid crystalline medium and the other substrate is either provided with an unprocessed alignment layer adjacent to the cholesteric liquid crystalline medium or is not provided with an alignment layer. The invention is further related to a method of production of said light modulation element and to the use of said light modulation element in various types of optical and electro-optical devices, such as electro-optical displays, liquid crystal displays (LCDs), non-linear optic (NLO) devices, and optical information storage devices.
Type:
Application
Filed:
May 16, 2017
Publication date:
August 13, 2020
Applicant:
Merck Patent GmbH
Inventors:
Bernd FIEBRANZ, Peter BEST, Meike KRUMWIEDE, Simon SIEMIANOWSKI
Abstract: The present invention relates to liquid-crystalline media comprising one or more pleochroic compounds, and one or more compounds selected from the group of compounds of formulae I, II and III, in which the groups have the meanings as set forth in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
Type:
Application
Filed:
January 20, 2017
Publication date:
August 13, 2020
Applicant:
Merck Patent GmbH
Inventors:
Michael WITTEK, Dagmar KLASS, Peer KIRSCH
Abstract: The present invention relates to the use of spray-dried sorbitol, such as ParteckĀ® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.
Type:
Application
Filed:
May 10, 2017
Publication date:
August 13, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Dieter LUBDA, Mengyao ZHENG, Alessandro Giuseppe ELIA, Nicole DI GALLO
Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof as cell culture additives to reduce the trisulfide levels in proteins produced in cell culture.
Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound and at least one compound of formula CO-1, wherein L31, L32, A31, and R31 have one of the meanings as given in claim 1. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I, and one or more compounds selected from the group of the compounds of the formulae II and III and/or IV, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
August 11, 2020
Assignee:
MERCK PATENT GMBH
Inventors:
Michael Junge, Volker Reiffenrath, Elvira Montenegro, Michael Wittek, Markus Czanta
Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
August 11, 2020
Assignees:
Merck Patent GmbH, Pfizer Inc.
Inventors:
Claudia Wilm, Klaus Schneider, Heike Dahmen
Abstract: An electronic component (10) comprising a plurality of switching elements (1) which comprise, in this sequence, a first electrode (16), a molecular layer (18) bonded to a substrate, and a second electrode (20), where the molecular layer essentially consists of molecules (M) which contain a connecting group (V) and an end group (E) having a polar or ionic function, is suitable as memristive device for digital information storage.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
August 11, 2020
Assignee:
MERCK PATENT GMBH
Inventors:
Peer Kirsch, Qiong Tong, Andreas Ruhl, Marc Tornow, Achyut Bora
Abstract: The present invention relates to thiadiazoloquinoxaline derivatives of the formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, r and s have the meanings indicated in Claim 1, to processes and intermediates for the preparation thereof, to the use of the compounds of the formula I for optical, electro-optical and electronic purposes, in particular in liquid-crystal media and in devices for regulating the passage of energy from an outside space into an inside space, and to these LC media and the devices comprising these media.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
August 11, 2020
Assignee:
Merck Patent GmbH
Inventors:
Peer Kirsch, Andreas Ruhl, Susann Gunst, Michael Junge, Ursula Patwal, Mila Fischer
Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal media comprising them, and to the use of the polymerizable compounds and liquid crystalline media for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in liquid crystalline displays of the polymer sustained alignment type.
Type:
Application
Filed:
April 22, 2020
Publication date:
August 6, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Qiong TONG, Nico SCHWEBEL, Constanze BROCKE, Kaja Christina DEING, Julian VOGT, Elisabeth MEYER
Abstract: The invention relates to a medium comprising at least 60% of one or more compounds of formula I wherein R11, R12, MG11, MG12 and Sp1 have the meaning given herein below, to the use of such media in liquid crystal devices, in particular in flexoelectric liquid crystal devices, and to a flexoelectric liquid crystal device comprising a liquid crystal medium according to the present invention.
Type:
Application
Filed:
November 18, 2016
Publication date:
August 6, 2020
Applicant:
Merck Patent GmbH
Inventors:
Simon SIEMIANOWSKI, Konstantin SCHNEIDER
Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.
Abstract: The present invention relates to the use of hydrophilic compounds of the formula I as photopolymerisation initiators of polymerisable substance mixtures which comprise unsaturated compounds, or for the photochemical crosslinking of linear polymers, in which the parameters have the meaning indicated in Claim 1, to sealants for liquid-crystal displays which comprise the hydrophilic photoinitiators, to novel hydrophilic photoinitiators of the formula I, and to the liquid-crystal displays produced using these sealants.
Type:
Application
Filed:
October 5, 2016
Publication date:
August 6, 2020
Applicant:
Merck Patent GmbH
Inventors:
Peer KIRSCH, Qiong TONG, Alexander HAHN, Leo WEEGELS, Steffen GNAUCK, Sven SCHUEPFER, Peter LEONHARD, Claudia ENDERS